James L Klosky1, Kathryn M Russell1, Jessica L Simmons1, Rebecca H Foster2,3, Kelly Peck1,4, Daniel M Green5,6, Melissa M Hudson5,6. 1. Department of Psychology, St. Jude Children's Research Hospital, Memphis, Tennessee. 2. Department of Psychology, St. Louis Children's Hospital, St. Louis, Missouri. 3. Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri. 4. Department of Psychology, University of Mississippi, Oxford, Mississippi. 5. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 6. Department of Epidemiology & Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.
Abstract
BACKGROUND: Among those 9-26 years of age, vaccination can prevent specific types of genital human papillomavirus (HPV), the most common sexually transmitted infection and cause of cervical and other cancers. The objective of this study was to estimate the prevalence of and factors associated with HPV vaccine initiation and completion among females surviving childhood cancer. PROCEDURE: One-hundred fourteen young adults and 230 mothers with daughters surviving childhood cancer completed surveys querying HPV vaccination history along with medical and sociodemographic factors potentially associated with vaccination outcomes. Vaccination rate differences by age necessitated analysis of outcomes by age group: 9-13 years (preadolescents), 14-17 years (adolescents), and 18-26 years (young adults). Multivariable logistic regression was utilized to identify factors associated with HPV vaccination outcomes. RESULTS: Overall, 34.6% (119/344) of survivors initiated and 20.9% (72/344) completed HPV vaccination. Preadolescents were least likely to have initiated vaccination (P < 0.001). Physician recommendation was associated with initiation across age groups (OR = 6.81-11.96, Ps < 0.001-.01), whereas older age at diagnosis (≥12 years of age) was associated with lower vaccination initiation among young adults only (OR = 0.28; 95%CI, 0.10-0.76, P = 0.012). Physician recommendation (OR = 7.54; 95%CI, 1.19-47.69, P = 0.032; adolescent group) and greater treatment intensity (OR = 5.25; 95%CI, 1.00-27.61, P = 0.050; young adult group) were associated with vaccine completion, whereas being non-White was associated with decreased vaccination completion (OR = 0.17; 95%CI, 0.05-0.66, P = 0.010; adolescent group). CONCLUSIONS: A minority of youths surviving childhood cancer have initiated or completed HPV vaccination. Strategies to increase vaccination among survivors are discussed.
BACKGROUND: Among those 9-26 years of age, vaccination can prevent specific types of genital human papillomavirus (HPV), the most common sexually transmitted infection and cause of cervical and other cancers. The objective of this study was to estimate the prevalence of and factors associated with HPV vaccine initiation and completion among females surviving childhood cancer. PROCEDURE: One-hundred fourteen young adults and 230 mothers with daughters surviving childhood cancer completed surveys querying HPV vaccination history along with medical and sociodemographic factors potentially associated with vaccination outcomes. Vaccination rate differences by age necessitated analysis of outcomes by age group: 9-13 years (preadolescents), 14-17 years (adolescents), and 18-26 years (young adults). Multivariable logistic regression was utilized to identify factors associated with HPV vaccination outcomes. RESULTS: Overall, 34.6% (119/344) of survivors initiated and 20.9% (72/344) completed HPV vaccination. Preadolescents were least likely to have initiated vaccination (P < 0.001). Physician recommendation was associated with initiation across age groups (OR = 6.81-11.96, Ps < 0.001-.01), whereas older age at diagnosis (≥12 years of age) was associated with lower vaccination initiation among young adults only (OR = 0.28; 95%CI, 0.10-0.76, P = 0.012). Physician recommendation (OR = 7.54; 95%CI, 1.19-47.69, P = 0.032; adolescent group) and greater treatment intensity (OR = 5.25; 95%CI, 1.00-27.61, P = 0.050; young adult group) were associated with vaccine completion, whereas being non-White was associated with decreased vaccination completion (OR = 0.17; 95%CI, 0.05-0.66, P = 0.010; adolescent group). CONCLUSIONS: A minority of youths surviving childhood cancer have initiated or completed HPV vaccination. Strategies to increase vaccination among survivors are discussed.
Authors: Paul L Reiter; Noel T Brewer; Sami L Gottlieb; Annie-Laurie McRee; Jennifer S Smith Journal: Soc Sci Med Date: 2009-06-18 Impact factor: 4.634
Authors: Lauri E Markowitz; Eileen F Dunne; Mona Saraiya; Herschel W Lawson; Harrell Chesson; Elizabeth R Unger Journal: MMWR Recomm Rep Date: 2007-03-23
Authors: Eileen F Dunne; Elizabeth R Unger; Maya Sternberg; Geraldine McQuillan; David C Swan; Sonya S Patel; Lauri E Markowitz Journal: JAMA Date: 2007-02-28 Impact factor: 56.272
Authors: Debbie Saslow; Philip E Castle; J Thomas Cox; Diane D Davey; Mark H Einstein; Daron G Ferris; Sue J Goldie; Diane M Harper; Walter Kinney; Anna-Barbara Moscicki; Kenneth L Noller; Cosette M Wheeler; Terri Ades; Kimberly S Andrews; Mary K Doroshenk; Kelly Green Kahn; Christy Schmidt; Omar Shafey; Robert A Smith; Edward E Partridge; Francisco Garcia Journal: CA Cancer J Clin Date: 2007 Jan-Feb Impact factor: 508.702
Authors: Branlyn E Werba; Wendy Hobbie; Anne E Kazak; Richard F Ittenbach; Anne F Reilly; Anna T Meadows Journal: Pediatr Blood Cancer Date: 2007-06-15 Impact factor: 3.167
Authors: Echo L Warner; Perla L Vaca Lopez; Deanna Kepka; Karely Mann; Heydon K Kaddas; Douglas Fair; Mark Fluchel; Elizabeth D Knackstedt; Samantha T Pannier; Laura Martel; Anne C Kirchhoff Journal: J Cancer Surviv Date: 2020-05-26 Impact factor: 4.442